XBIO

distress 2/10 · well-funded / low risk

$2.64-1%today-75% from 52w high

xeneticbio.com2 employeesFramingham, MABiotechnology

Revenue

pre-revenue

Liquidity

$7M

Runway

4.0 yrs

Shares 1y

+49%

Price & events

-4.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.1%

-6.0%

-9.0%

-15.7%

-0.4%

-27.3%

-37.9%

-89.5%

-87.7%

All

Overview

Market Cap: $6.05M
Volume: 660
52 Week Range: $2.02 – $10.36
Total Shares: 2.29M
Float Shares: 1.82M
Short %: 1.07%
% Held by Insiders: 15.77%
% Held by Institutions: 7.38%
RVOL: 0.04x
Beta: 2.20

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

2024-11-01partnershipDNase I · Extended research collaboration with The Scripps Research Institute, providing up to $400k additional funding and 12-month term extension.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 2,291,056 · 2 offerings/1y · 0 PIPEs

2025-10-148-Kmaterial_agreement
2025-10-14424B5offering
2025-10-10424B5offering
2024-11-078-Kmaterial_agreement
2024-11-01EFFECTshelf_effective
2024-10-21S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2025-04-09HC Wainwright & Co.Neutral
2025-03-20HC Wainwright & Co.Neutral
2024-12-05HC Wainwright & Co.Neutral
2024-11-22HC Wainwright & Co.Neutral
2024-08-20HC Wainwright & Co.Neutral

Competitors

none identified